

## SGLT2 Inhibitors and Combinations

Member	Information
WICHINC!	mormation

1. Last Name:	2. First Na	2. First Name:5. Gender:		
3. Trillium ID #:	4. Date of Birth:	5. Gender:		
Prescriber Information				
1. Prescriber Name:		_ 2. NPI #:		
3. Requestor Name (Nurse/Office	e Staff):			
4. Mailing Address:	Cit			
5. Phone #:	Ext Fa	ax #:		
Drug Information				
1. Drug Name:	2. Strength:	_ 3. Quantity per 30 Days:		
4. Length of Therapy: 🗆 30 Days	□ 60 Days □ 90 Days □ 120 Days	□ 180 Days □ 365 Days □ Other		
Clinical Information				
-	-	red and non preferred products 1-6):		
1. Does the member have a diagno				
	sis of Type 2 Diabetes?  Yes  No			
	failure or insufficient response to met	formin therapy or other metformin		
containing products?   Yes				
	dication or adverse event to metformi			
	CVD, heart failure, or Chronic Kidney I			
_	risk for ASCVD as defined as ≥ 55 year , dyslipidemia, or albuminuria)? □ <b>Ye</b>	s of age with $\geq$ 2 additional risk factors (e.g. s $\Box$ No		
		ember tried and failed or experienced an		
	•	ical reason that preferred products cannot b		
tried? 🗆 Yes 🗆 No				
-		n preferred and non-preferred products:		
1. Has the member improved while request)	e on this medication?   Yes  No (Mo	edical Documentation should be attached to this		
2. Are individual clinical goals that	were set by the provider being met? I	🗆 Yes 🗆 No		
3. Is the member continuing to ma	ke adequate progress towards treatm	ent goals? 🗆 Yes 🗆 No		
Signature of Prescriber:		Date:		

(Prescriber Signature Mandatory) I certify that the information provided is accurate and complete to the best of my knowledge, and I understand that any falsification, omission, or concealment of material fact may subject me to civil or criminal liability.